Ovarian Cancer Immunotherapy: Preclinical Models and Emerging Therapeutics
Immunotherapy has emerged as one of the most promising approaches for ovarian cancer treatment. The tumor microenvironment (TME) is a key factor to consider when stimulating antitumoral responses as it consists largely of tumor promoting immunosuppressive cell types that attenuate antitumor immunity...
Main Authors: | Curtis W. McCloskey, Galaxia M. Rodriguez, Kristianne J. C. Galpin, Barbara C. Vanderhyden |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2018-07-01
|
Series: | Cancers |
Subjects: | |
Online Access: | http://www.mdpi.com/2072-6694/10/8/244 |
Similar Items
-
The Tumor Microenvironment of Epithelial Ovarian Cancer and Its Influence on Response to Immunotherapy
by: Galaxia M. Rodriguez, et al.
Published: (2018-07-01) -
Ovarian Cancer Immunotherapy: Turning up the Heat
by: Eleonora Ghisoni, et al.
Published: (2019-06-01) -
Tumor Burden and Immunotherapy: Impact on Immune Infiltration and Therapeutic Outcomes
by: Samuel I. Kim, et al.
Published: (2021-02-01) -
Recent Advancements in Nanomedicine for ‘Cold’ Tumor Immunotherapy
by: Qinjun Chen, et al.
Published: (2021-03-01) -
The tumor microenvironment as a metabolic barrier to effector T cells and immunotherapy
by: Aaron R Lim, et al.
Published: (2020-05-01)